Elicera Therapeutics is developing ELC-100 as a potential treatment for neuroendocrine tumors (NET). The drug candidate, based on an oncolytic virus, exerts its therapeutic effect by selectively infecting and killing neuroendocrine cancer cells. The Phase I/IIa clinical trial aims to identify the maximum tolerated dose (MTD) and assess the treatment's safety in patients.

Based on new information from the contract research organization (CRO) responsible for compiling the study database and collecting and analyzing data, the database cannot be closed before the summer as previously planned. The delay is partly due to the study, which has been ongoing since 2016, having to switch to a new database solution after the original database was discontinued. This has required additional time to migrate and validate data to a new platform. The CRO now estimates that the database can be closed by the fall, with final reporting expected before the end of 2025.

"We recognize that the unexpected delay of the study report until the fourth quarter of 2025 may cause frustration among our shareholders and stakeholders, and we share this sentiment. The technical transition to a new database platform has proven more complex than anticipated, which we could not foresee in our original planning. Our priority is to ensure robust and reliable study results, and we are working intensively to complete the process as quickly as possible, with the goal of delivering high-quality data by Q4 2025 at the latest," says Jamal El-Mosleh, CEO of Elicera Therapeutics.